CA
OLMA icon

CoreCap Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

CoreCap Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-249
Closed -$936 – 3091
2025
Q1 		$936 Buy
249
+180
+261% +$905 ﹤0.01% 2537
2024
Q4 		$402 Buy
+69
New +$689 ﹤0.01% 2583

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CoreCap Advisors's OLMA Position: Q2 2025 in Review

CoreCap Advisors sold out of Olema Pharmaceuticals (OLMA) in Q2 2025, closing a stake of 249 shares — an estimated $936 sold.

CoreCap Advisors first reported a position in OLMA in Q4 2024 and held it in 2 quarters. The position peaked at $936 in Q1 2025. 122 funds tracked by Wall St. Rank hold OLMA as of Q2 2025.

  • CoreCap Advisors reported no remaining Olema Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 249 Olema Pharmaceuticals shares in Q2 2025, an estimated $936.
  • CoreCap Advisors first reported a position in Olema Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Olema Pharmaceuticals position peaked at $936 in Q1 2025.
  • 122 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.